Antibiotic resistance is a global concern that threatens our ability to prevent and treat bacterial infections in humans and ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

Tulane University researchers have developed a CRISPR-based test that diagnoses Pneumocystis jirovecii pneumonia (PJP)—a life-threatening fungal infection primarily affecting children and ...

Researchers at the Arc Institute, Stanford University, and NVIDIA have developed Evo 2, an advanced AI model capable of ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Recent breakthroughs and regulatory shifts in gene editing might be the key to moving from treating the symptoms of diseases ...

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But ...

RNA-based therapeutics have rapidly emerged over the past decade, offering a new class of medicines that differ significantly from conventional drugs. These therapies can be programmed to target or ...

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

A specific gene variant seen in people is likely one of many that contributed to the development of language in modern humans ...

A new study links a particular gene to the ancient origins of spoken language, proposing that a protein variant found only in ...

For the latest research, scientists in his lab at New York's Rockefeller University used CRISPR gene editing to replace the NOVA1 protein found in mice with the exclusively human type to test the ...